Decoy Therapeutics is trading 5.12% down at $1.76, with no fresh company-specific announcement identified to explain the October 2 pre-market decline. - The October 1 investor presentation was announced in advance; the preclinical update was reported September 29. - Biotech-sector signals were mixed: one report showed XBI down 2.01% pre-market, while another put it up about 0.9% at 7:46 a.m. ET.